CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...